EUVIMEDOdkrijte EUVIMED
Crossref

Assessing the Impact of GLP‐1R Agonists in Post‐sinus Surgery Management

David Hoying iD, David C Kaelber, Mohamad R Chaaban

Otolaryngology–Head and Neck Surgery · 2026

DOI: 10.1002/ohn.70072 ↗

At a glance

Journal article in Otolaryngology–Head and Neck Surgery, 2026. Written by David Hoying and 2 co-authors. Institution: Case Western Reserve University School of Medicine, Cleveland, Ohio, USA. Major MEDLINE topics: Glucagon-Like Peptide-1 Receptor Agonists, Rhinitis, Sinusitis, Endoscopy. Cited 3 times so far (Crossref); 23 references.

AbstraktSubjectsBibliografické údajeCiteRelated studies

Abstract (original language)

Objective

Emerging evidence suggests a potential association between chronic rhinosinusitis (CRS) and obesity. With the increasing utilization of weight loss medications in the management of obesity, we aimed to assess the impact of glucagon‐like peptide‐1 receptor agonist (GLP‐1RA) prescription on the revision rate of functional endoscopic sinus surgery (FESS) and the use of biologics post‐FESS. Study Design Retrospective cohort analysis.

Setting

US Collaborative Network within the TriNetX Analytics platform.

Methods

We queried the TriNetX Analytics platform for all adult CRS with nasal polyps (CRSwNP) patients with obesity who have undergone at least one prior FESS (based on Current Procedural Terminology [CPT] code). The incidence of revision surgery and first‐time biologic prescriptions (dupilumab, mepolizumab, and omalizumab) within a 1‐ and 5‐year follow‐up period was assessed, comparing those with and without GLP‐1R agonist prescriptions.

Results

After 1:1 propensity matching, there were a total of 1391 patients in each patient group. The GLP‐1RA cohort had a significantly reduced incidence of revision FESS compared to the non‐GLP‐1RA cohort at 1‐year (RR: 0.64; 95% CI: 0.41‐0.98, P = .04) and 5‐year follow‐up periods (risk ratio [RR]: 0.60; 95% CI: 0.44‐0.0.81, P = .001). At the 5‐year follow‐up, the first‐time biologic prescription was lower in the GLP‐1RA cohort compared to the non‐GLP‐1RA cohort (RR: 0.72; 95% CI: 0.52‐0.98, P = .04).

Conclusion

Our results indicate that GLP‐1RAs are associated with reduced postoperative revision FESS at up to a 5‐year follow‐up in CRSwNP patients. Future mechanistic and prospective studies are needed to confirm the association between GLP‐1R agonists and improved post‐sinus surgery outcomes identified in this study.

Subjects

MeSH terms (MEDLINE)

Glucagon-Like Peptide-1 Receptor AgonistsRhinitisSinusitisEndoscopyObesityNasal PolypsHumansRetrospective StudiesMaleFemaleMiddle AgedAdultReoperationChronic Disease

Author keywords

GLP‐1RATriNetXchronic rhinosinusitisobesity

Substances

Glucagon-Like Peptide-1 Receptor Agonists

Authors and institutions

  • Case Western Reserve University School of Medicine, Cleveland, Ohio, USA.
  • Departments of Internal Medicine, Pediatrics, and Population and Quantitative Health Sciences, Case Western Reserve University, Cleveland, Ohio, USA.
  • The Center for Clinical Informatics Research and Education, The MetroHealth System, Cleveland, Ohio, USA.
  • Head and Neck Institute, Cleveland Clinic, Cleveland, Ohio, USA.

ORCID profiles: David Hoying

Cite

APA

Hoying, D., Kaelber, D. C., & Chaaban, M. R. (2026). Assessing the Impact of GLP‐1R Agonists in Post‐sinus Surgery Management. Otolaryngology–Head and Neck Surgery. https://doi.org/10.1002/ohn.70072

Vancouver

Hoying D, Kaelber DC, Chaaban MR. Assessing the Impact of GLP‐1R Agonists in Post‐sinus Surgery Management. Otolaryngology–Head and Neck Surgery. 2026. doi:10.1002/ohn.70072

BibTeX
@article{Hoying2026,
  author = {Hoying, David and Kaelber, David C and Chaaban, Mohamad R},
  title = {Assessing the Impact of GLP‐1R Agonists in Post‐sinus Surgery Management},
  journal = {Otolaryngology–Head and Neck Surgery},
  year = {2026},
  doi = {10.1002/ohn.70072}
}
Start for free →